These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29434148)

  • 21. [Diffuse large B-cell lymphoma complicated with drug-induced vasculitis during administration of pegfilgrastim].
    Ito Y; Noda K; Aiba K; Yano S; Fujii T
    Rinsho Ketsueki; 2017; 58(11):2238-2242. PubMed ID: 29212975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
    Molineux G
    Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
    Frampton JE; Keating GM
    BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
    Pawloski PA; Larsen M; Thoresen A; Giordana MD
    J Oncol Pharm Pract; 2016 Jun; 22(3):423-9. PubMed ID: 25956422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation.
    Wang X; Ren J; Liang X; He P
    Hematology; 2021 Dec; 26(1):950-955. PubMed ID: 34904529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
    Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
    Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
    George S; Yunus F; Case D; Yang BB; Hackett J; Shogan JE; Meza LA; Neumann TA; Liang BC
    Leuk Lymphoma; 2003 Oct; 44(10):1691-6. PubMed ID: 14692520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
    Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
    J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
    Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
    Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
    Leung M; Florendo J; Kano J; Marr-Del Monte T; Higgins B; Myers R; Menon T; Jones G
    Support Care Cancer; 2015 Jun; 23(6):1669-77. PubMed ID: 25421443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegfilgrastim use during chemotherapy: current and future applications.
    Wolf T; Densmore JJ
    Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database.
    Oshima Y; Takahashi S; Tani K; Tojo A
    Cytokine; 2019 Jul; 119():47-51. PubMed ID: 30875590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim.
    Brokx S; Scrocchi L; Shah N; Dowd J
    Biologicals; 2017 Jul; 48():28-38. PubMed ID: 28619479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J
    Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Mori H; Kubo M; Kai M; Kurata K; Yamada M; Nakamura M
    Anticancer Res; 2018 Jul; 38(7):4381-4386. PubMed ID: 29970577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
    Yoo N; Lee HR; Shin SH; Sohn KY; Kim HJ; Han YH; Chong S; Kim MH; Yoon SY; Kim JW
    Cancer Lett; 2016 Jul; 377(1):25-31. PubMed ID: 27105612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.